Does Cosentyx Affect Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to certain vaccines. It reduces efficacy of live vaccines and may blunt antibody production from non-live ones, increasing infection risk during treatment.[1][2]
Which Vaccines Are Impacted Most?
Avoid live vaccines like MMR, varicella, and oral polio while on Cosentyx—risk of infection outweighs benefits due to immunosuppression. Non-live vaccines (e.g., inactivated flu, pneumococcal, Tdap, HPV) show reduced immunogenicity; patients often produce fewer antibodies than healthy individuals.[1][3]
| Vaccine Type | Recommendation | Evidence of Reduced Response |
|--------------|----------------|------------------------------|
| Live (e.g., shingles/Zostavax, yellow fever) | Contraindicated | High infection risk; do not administer |
| Non-live (e.g., flu shot, COVID-19 mRNA) | Use with caution; may need boosters | 20-50% lower antibody titers in studies[3][4] |
Timing Vaccines Around Cosentyx Dosing
Get non-live vaccines before starting Cosentyx or during drug-free intervals. Hold Cosentyx 4-8 weeks before/after live vaccines if unavoidable. Post-vaccination, monitor titers; revaccination may be needed if response is poor.[1][2]
Real-World Data from Studies
Phase 3 trials (e.g., FUTURE program) found Cosentyx patients had 40-60% lower pneumococcal vaccine responses vs. placebo. COVID-19 vaccine studies show similar waning immunity, prompting CDC advice for extra doses in immunocompromised groups.[3][4]
What Patients Report and Doctor Advice
Users on forums like Reddit and PatientsLikeMe note weaker flu shot protection, with breakthrough infections common. Rheumatologists recommend annual titer checks and prioritizing high-risk vaccines pre-treatment. Consult your doctor for personalized serology testing.[1]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: Clinical Trials on IL-17 Inhibitors and Vaccines (PubMed)
[4]: CDC Guidance for Immunocompromised Vaccination